Bial Nears Finish Line in Trial for Genetic Parkinson's Drug

PORTO, Portugal – January 27, 2026 – In a significant development for the future of Parkinson's disease treatment, Portuguese biopharmaceutical company Bial has announced a critical milestone in a late-stage clinical trial for a potential first-in-class therapy. The company confirmed that 75% of patients enrolled in its Phase 2b ACTIVATE study have now completed the 78-week double-blind treatment period, moving a promising drug for a specific genetic form of Parkinson's one step closer to reality.

The study is evaluating BIA 28-6156, a novel oral medication designed for patients with Parkinson’s disease who carry a mutation in the glucocerebrosidase 1 (GBA1) gene. This milestone keeps the study on track for its anticipated completion in 2026, fueling optimism for what could become the first therapy to directly modify the underlying cause of this aggressive form of the disease.

Targeting the Genetic Roots of Parkinson's

Parkinson's disease, the world's second most common neurodegenerative disorder, affects more than 10 million people. While often viewed as a single condition, researchers increasingly understand it as a collection of related disorders with different underlying causes. One of the most significant discoveries in recent years has been the role of the GBA1 gene.

Mutations in this gene represent the single largest genetic risk factor for developing Parkinson's disease, present in 5% to 15% of all patients. The resulting condition, known as GBA-associated Parkinson’s disease (GBA-PD), presents a particularly challenging clinical picture. Compared to individuals with non-genetic Parkinson's, GBA-PD patients often experience an earlier onset of symptoms. Their disease also tends to progress more rapidly, leading to more severe motor and cognitive impairments, including a significantly higher risk of dementia, and a worse overall prognosis.

Currently, no treatments exist to slow or halt this aggressive progression. Standard Parkinson's therapies manage symptoms by replacing dopamine but do nothing to address the root cause of cell death. This profound unmet medical need has made GBA-PD a key focus for researchers seeking to develop the first true disease-modifying therapies.

A First-in-Class Activator for the Brain

Bial's BIA 28-6156 represents a novel strategy aimed directly at the biological defect caused by GBA1 mutations. The gene is responsible for producing an essential enzyme, beta-glucocerebrosidase (GCase), which acts as a critical part of the cell's waste disposal system within structures called lysosomes. In GBA-PD, the faulty gene leads to reduced GCase activity, disrupting this system and causing a toxic buildup of substances, including the alpha-synuclein protein clumps that are a hallmark of Parkinson's pathology.

BIA 28-6156 is designed as a small molecule, once-daily oral drug that acts as an allosteric activator of GCase. In simple terms, it binds to the enzyme and boosts its activity, helping to restore normal lysosomal function and clear out the cellular waste. Crucially, preclinical and early-phase clinical studies have shown that BIA 28-6156 is a small molecule capable of crossing the highly selective blood-brain barrier. This allows it to reach its target within the central nervous system, a hurdle that has thwarted many previous attempts to treat the neurological aspects of GCase deficiency.

Data from earlier Phase 1 trials was promising, showing the drug was well-tolerated and achieved pharmacologically active concentrations in both blood plasma and cerebrospinal fluid, confirming it reaches the brain. This scientific foundation underpins the hope that BIA 28-6156 could be the first drug to directly intervene in the disease process within the brain for GBA-PD patients.

Hope and High Stakes in the ACTIVATE Study

The ACTIVATE study is a large-scale, international effort, reflecting the global urgency to find a solution for GBA-PD. Recruitment for the trial was completed ahead of schedule, enrolling 273 genetically confirmed patients across 85 clinical sites in 11 countries throughout Europe and North America. This rapid enrollment underscores the strong engagement of the patient community and their eagerness to participate in research that could change their future.

Perhaps even more telling is the study's strong patient retention. The trial demands a significant commitment, with a treatment period lasting a year and a half. That the vast majority of participants have remained in the study speaks to their dedication and the hope they place in the potential of this new therapy. In a statement, Bial CEO António Portela acknowledged this collaborative spirit.

“We are witnessing growing enthusiasm across the Parkinson’s community and are truly excited to be at the forefront of a potential and much-needed disease-modifying treatment for people living with GBA-PD,” said Portela. “We are deeply grateful to the patients and their families for their extraordinary commitment, and to the global clinical community whose efforts continue to drive progress.”

Bial's Calculated Bet on Niche Neurology

For Bial, the progress of BIA 28-6156 is a validation of its long-term corporate strategy. The company has carved out a niche by focusing on complex areas of high unmet need, specifically neurosciences and rare diseases, and consistently reinvesting over 20% of its annual revenue into research and development.

This focused approach allows the company to compete in a field dominated by pharmaceutical giants by concentrating its resources on specific, well-defined biological targets. While other companies are exploring different avenues for GBA-PD, including gene therapy and other molecular pathways, Bial’s BIA 28-6156 is considered the leading clinical-stage asset in the GCase activator class.

With the final patient visit for the ACTIVATE study anticipated in April 2026, the entire Parkinson's research community is now looking ahead to the release of topline results in mid-2026. A positive outcome would not only be a transformative event for Bial but would also represent a landmark victory for precision medicine in neurodegeneration. It would prove that by targeting a specific genetic underpinning of a disease, it is possible to develop therapies that do more than just mask symptoms. For the thousands of patients and families living with the aggressive advance of GBA-associated Parkinson's, the wait for those results carries the weight of a potential new beginning.